Jaguar Health, Inc. (NASDAQ:JAGX) | Finanzwire

Basculer en Français

8295	Companies
114833	Keywords
55274	Articles
62430	Press releases

Home
Companies
Jaguar Health, Inc.

BRIEF

published on 11/19/2024 at 15:35, 1 day 19 hours ago

Napo Therapeutics Awarded "Best Pharmaceuticals Innovator of the Year - Europe"

Crofelemer Awards Rare Diseases Napo Therapeutics Innovative Pharmaceuticals
PRESS RELEASE

published on 11/19/2024 at 15:30, 1 day 19 hours ago

Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”
Jaguar Health's Napo Therapeutics awarded 'Best Pharmaceuticals Innovator of the Year - Europe' for expanding access to crofelemer in Europe for orphan and rare diseases. Partnering with Jaguar and Napo Pharmaceuticals for clinical studies

Crofelemer Jaguar Health Rare Diseases Orphan Diseases Napo Therapeutics
BRIEF

published on 11/13/2024 at 14:05, 7 days 20 hours ago

Jaguar Health Reports Strong Q3 2024 Financial Performance

Financial Results Crofelemer Jaguar Health Q3 2024 Cancer Supportive Care
PRESS RELEASE

published on 11/13/2024 at 14:00, 7 days 20 hours ago

Jaguar Health Reports Third Quarter 2024 Financial Results
Jaguar Health, Inc. reports a 14% revenue increase in Q3 2024, introduces Gelclair commercial launch. Initiates Phase 2 trials and IIT studies. Hosts investor webcast on November 13

Revenue Increase Jaguar Health Q3 2024 Phase 2 Trials Gelclair
BRIEF

published on 11/11/2024 at 14:35, 9 days 20 hours ago

Jaguar Health to Discuss Q3 2024 Financials in Upcoming Investor Webcast

Napo Pharmaceuticals Crofelemer Investor Webcast Jaguar Health Q3 Financials
PRESS RELEASE

published on 11/11/2024 at 14:30, 9 days 20 hours ago

Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates
Jaguar Health, Inc. (NASDAQ:JAGX) to conduct investor webcast on November 13, 2024 at 8:30 a.m. Eastern to review Q3 2024 financials and provide corporate updates

Investor Webcast Jaguar Health Corporate Updates Q3 Financials NASDAQ:JAGX
BRIEF

published on 11/06/2024 at 16:05, 14 days 18 hours ago

FDA Renews Approval for Canalevia-CA1, Jaguar Health's Canine Diarrhea Drug

FDA Approval Veterinary Medicine Jaguar Health Canalevia-CA1 Chemotherapy-induced Diarrhea
PRESS RELEASE

published on 11/06/2024 at 16:00, 14 days 18 hours ago

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs
Jaguar Health, Inc. announces FDA conditional approval renewal of Canalevia-CA1 for chemotherapy-induced diarrhea in dogs. Canalevia-CA1, a crofelemer tablet, is available from major U.S. veterinary distributors

Crofelemer FDA Approval Jaguar Health Canalevia-CA1 Chemotherapy-induced Diarrhea
BRIEF

published on 11/04/2024 at 14:35, 16 days 20 hours ago

Crofelemer Shows Promise in Managing Cancer Therapy-Related Diarrhea in Breast Cancer Patients

Crofelemer Jaguar Health OnTarget Trial Breast Cancer SABCS
PRESS RELEASE

published on 11/04/2024 at 14:30, 16 days 20 hours ago

Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)
Napo Pharmaceuticals announces acceptance of late-breaking abstract on crofelemer results for breast cancer patients in OnTarget trial, presented at SABCS 2024

Napo Pharmaceuticals Crofelemer OnTarget Trial Breast Cancer Late-breaking Abstract

Accesswire

Published on 11/21/2024 at 10:03, 50 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 53 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 53 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 10 hours 18 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 28 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 10:30, 23 minutes ago

MS Industrie AG publishes unaudited key figures for the first 3 quarters 2024
Published on 11/21/2024 at 10:04, 48 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 51 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 53 minutes ago

Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 53 minutes ago

Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV

Les Echos

Published on 11/21/2024 at 06:58, 3 hours 55 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 33 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 17 hours 8 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 17 hours 8 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 3 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE